Mark D. Pegram, MD
Advertisement
Articles by Mark D. Pegram, MD
Advertisement
Latest Updated Articles
Novel Therapy for Relapsed/Refractory HR+ BC: Oral SERDsPublished: August 1st 2022 | Updated:
Real-World Use of CDK4/6 Inhibition in HR+/HER2- Breast CancerPublished: July 11th 2022 | Updated:
Expert Perspectives on Optimizing Biomarker Testing in Advanced HR+/HER2- Breast CancerPublished: July 1st 2024 | Updated:
The Evolution of Early-Stage HR+ Breast Cancer ManagementPublished: August 5th 2022 | Updated:
- Frontline Combination Strategies in HR+/HER2- BC
Published: July 18th 2022 | Updated:
- Looking Ahead: Expert Future Perspectives in the HR+ Breast Cancer Landscape
Published: August 6th 2024 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
2
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
3
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
4
Orca-T With Reduced-Intensity Conditioning Yields Robust Efficacy in Hematologic Malignancies
5